Thursday, November 12, 2026

U.S. Treasury Yields Hit 5.0%, Japan Bonds Follow—Global AI Infrastructure Costs Rise

The U.S. 10-year Treasury yield climbed to 5.0% from 4.31%, while Japan's equivalent benchmark rose to 2.641%. The synchronized move across two of the world's largest bond markets is lifting borrowing costs for AI data centers, chip fabs, and compute facilities globally.

LM Salvado
LM Salvado

May 25, 2026

U.S. Treasury Yields Hit 5.0%, Japan Bonds Follow—Global AI Infrastructure Costs Rise
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The U.S. 10-year Treasury yield reached 5.0%, up from 4.31%1. Simultaneously, Japan's 10-year Government Bond yield rose to 2.641% from 2.478%1. Two of the world's largest bond markets moved in the same direction—a signal of broad global capital repricing.

For AI infrastructure, the timing is difficult. Data centers, chip fabrication plants, and compute facilities are capital-intensive. They rely on debt markets. New issuances in H2 2026 will carry higher coupons than deals struck in 2024 or 2025.

The Japan move carries particular global weight. For years, near-zero JGB yields anchored carry trades worldwide—suppressing borrowing costs from Frankfurt to Singapore. The Bank of Japan's ongoing normalization removes a structural source of cheap global liquidity. The ripple effect reaches emerging market borrowers most acutely.

Higher risk-free rates compress the present value of future cash flows. AI and tech companies trade on earnings projected years out. A 10-year yield at 5.0% versus 4.31% shifts the valuation math on every long-duration growth asset, regardless of where those companies are listed.

Corporate behavior is already adjusting. Birkenstock's $250 million accelerated share repurchase, executed with Goldman Sachs1, reflects a wider pattern: in a higher-rate world, capital returns beat long-duration investment bets. European and Asian multinationals face the same calculus.

Credit markets transmit the shock directly. Investment-grade issuers face higher all-in borrowing costs. High-yield borrowers face tighter conditions. Leveraged buyouts—structurally dependent on cheap debt—become harder to underwrite profitably with a 5.0% risk-free floor.

Enterprise value-to-revenue multiples that AI infrastructure companies commanded in 2024 were priced against a lower discount rate. At 5.0% on the 10-year, those multiples face sustained downward pressure. The repricing is not a U.S. story. It is a global one.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com